Typically benign, slow-growing tumors that arise from cells in the pituitary gland
- Presenting symptoms include neurologic deficits, visual changes including diplopia, and headaches.
- Subtypes (hormonal): prolactinoma (PRL) 25–40%, nonfunctioning pituitary adenomas 30%, somatotroph adenoma (growth hormone [GH]) 15–20%, corticotroph adenoma (adrenocorticotropic hormone [ACTH]) 5–10%, thyrotroph adenoma (thyroid-stimulating hormone [TSH]) <1%, gonadotropinoma (luteinizing hormone/follicle-stimulating hormone [LH/FSH]), mixed (1)[A]
- Defined as microadenoma <10 mm and macroadenoma ≥10 mm
- May secrete hormones and/or cause mass effects or visual changes
- Autopsy studies have found microadenomas in 3–27% and macroadenomas in <0.5% of people without any pituitary disorders.
- Clinically apparent pituitary tumors are seen in 18/100,000 persons.
Etiology and Pathophysiology
- Monoclonal adenohypophysial cell growth
- Hormonal effects of functional microadenomas often prompt diagnosis before mass effect.
- PRL increased by functional PRLs or inhibited dopaminergic suppression by stalk effect
Familial isolated pituitary adenomas: ~15% have mutations in the aryl hydrocarbon receptor–interacting protein gene (AIP); present at a younger age and are larger in size (2)
Multiple endocrine neoplasias
Commonly Associated Conditions
- McCune-Albright syndrome
- Multiple endocrine neoplasia type 1 (MEN1)
There's more to see -- the rest of this topic is available only to subscribers.